Date: 2016-05-04
Type of information: Nomination
Compound:
Company: Tiziana Life Sciences (UK)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On May 4, 2016 ,Tiziana Life Sciences, a clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, announced that it has further expanded its clinical development team with the key appointment of Robert Evans, PharmD. as Vice President of Clinical Sciences. Dr. Evans will report to James Tripp, Chief Operating Officer and Head of Clinical.
Prior to joining the Company, Dr. Evans served as Vice President of Clinical Development at Glenmark Pharmaceuticals and was responsible for providing project and clinical leadership across multiple programs focused on the treatment of oncology, respiratory and dermatology disorders. Prior to Glenmark, Dr. Evans served in scientific leadership roles in the Immunology and Inflammation Group at Regeneron Pharmaceutical.
Dr. Evans received his Bachelor of Science degree in Pharmacy from the University of Illinois, and a PharmD from the University of Kansas City, Kansas City Missouri. He completed Fellowships at St Jude Children’s Research Hospital and the University of Pittsburgh.
Tiziana Life Sciences' clinical development teams are working on its Bcl-3 candidate; which has a prominent role in the metastasis of mammary cancers, and has elucidated the mechanism of Bcl-3 action to be a regulator of cancer cell motility and has also determined that Bcl-3 inhibition suppresses cell motility in triple-negative, HER-2-positive PR- and ER-positive breast cancer sub-types, suggesting that Bcl-3 may be a master regulator of this metastatic property not only in aggressive breast cancers, but across the clinical spectrum of breast disease. The Company is preparing the IND package with the intention of progressing to clinical trials this year.
Financial terms:
Latest news:
